{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T19:30:55Z","timestamp":1792438255576,"version":"4.5.0"},"reference-count":208,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T00:00:00Z","timestamp":1680566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013965","name":"Eastern Virginia Medical School","doi-asserted-by":"publisher","award":["N\/a"],"award-info":[{"award-number":["N\/a"]}],"id":[{"id":"10.13039\/100013965","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The clinical significance of Epstein\u2013Barr virus (EBV) cannot be understated. Not only does it infect approximately 90% of the world\u2019s population, but it is also associated with numerous pathologies. Diseases linked to this virus include hematologic malignancies such as diffuse large B-cell lymphoma, Hodgkin lymphoma, Burkitt lymphoma, primary CNS lymphoma, and NK\/T-cell lymphoma, epithelial malignancies such as nasopharyngeal carcinoma and gastric cancer, autoimmune diseases such as multiple sclerosis, Graves\u2019 disease, and lupus. While treatment for these disease states is ever evolving, much work remains to more fully elucidate the relationship between EBV, its associated disease states, and their treatments. This paper begins with an overview of EBV latency and latency-associated proteins. It will then review EBV\u2019s contributions to select hematologic malignancies with a focus on the contribution of latent proteins as well as their associated management.<\/jats:p>","DOI":"10.3390\/cancers15072133","type":"journal-article","created":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T01:35:59Z","timestamp":1680572159000},"page":"2133","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["EBV and Lymphomagenesis"],"prefix":"10.3390","volume":"15","author":[{"given":"Daniel G.","family":"Sausen","sequence":"first","affiliation":[{"name":"School of Medicine, Eastern Virginia Medical School, Norfolk, VA 23507, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayeman","family":"Basith","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Eastern Virginia Medical School, Norfolk, VA 23507, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed","family":"Muqeemuddin","sequence":"additional","affiliation":[{"name":"Independent Researcher, Norfolk, VA 23510, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jcv.2018.03.001","article-title":"Primary Epstein-Barr virus infection","volume":"102","author":"Dunmire","year":"2018","journal-title":"J. Clin. Virol."},{"key":"ref_2","unstructured":"Mohseni, M., Boniface, M.P., and Graham, C. (2022). StatPearls, StatPearls Publishing."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/09674845.2021.1903683","article-title":"Infectious Mononucleosis: Diagnosis and clinical interpretation","volume":"78","author":"Naughton","year":"2021","journal-title":"Br. J. Biomed Sci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1128\/JVI.00382-17","article-title":"Asymptomatic Primary Infection with Epstein-Barr Virus: Observations on Young Adult Cases","volume":"91","author":"Abbott","year":"2017","journal-title":"J. Virol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.coviro.2021.11.013","article-title":"Epigenetic control of the Epstein-Barr lifecycle","volume":"52","author":"Guo","year":"2022","journal-title":"Curr. Opin. Virol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev-pathmechdis-012418-013023","article-title":"Epstein-Barr Virus and Cancer","volume":"14","author":"Farrell","year":"2019","journal-title":"Annu. Rev. Pathol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/ajh.26579","article-title":"EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk-stratification, and management","volume":"97","author":"Malpica","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"829943","DOI":"10.3389\/fimmu.2022.829943","article-title":"Killer Cell Immunoglobulin-Like Receptor Haplotype B Modulates Susceptibility to EBV-Associated Classic Hodgkin Lymphoma","volume":"13","author":"Jiang","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e2328","DOI":"10.1002\/rmv.2328","article-title":"EBV associated T- and NK-cell lymphoproliferative diseases: A comprehensive overview of clinical manifestations and novel therapeutic insights","volume":"32","author":"Shafiee","year":"2022","journal-title":"Rev. Med. Virol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"15088","DOI":"10.1038\/nrdp.2015.88","article-title":"Post-transplant lymphoproliferative disorders","volume":"2","author":"Dharnidharka","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_11","first-page":"e26314","article-title":"The Association of Epstein-Barr Virus With Cancer","volume":"14","author":"Patel","year":"2022","journal-title":"Cureus"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1182\/blood.2020008520","article-title":"EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity","volume":"137","author":"Gandhi","year":"2021","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Shechter, O., Sausen, D.G., Gallo, E.S., Dahari, H., and Borenstein, R. (2022). Epstein-Barr Virus (EBV) Epithelial Associated Malignancies: Exploring Pathologies and Current Treatments. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232214389"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s10120-021-01215-3","article-title":"Landscape of EBV-positive gastric cancer","volume":"24","author":"Saito","year":"2021","journal-title":"Gastric Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1158\/1055-9965.EPI-20-1702","article-title":"The Evolving Epidemiology of Nasopharyngeal Carcinoma","volume":"30","author":"Chang","year":"2021","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00432-021-03824-y","article-title":"Estimating the global burden of Epstein-Barr virus-related cancers","volume":"148","author":"Wong","year":"2022","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1750-9378-9-38","article-title":"Global burden of deaths from Epstein-Barr virus attributable malignancies 1990\u20132010","volume":"9","author":"Khan","year":"2014","journal-title":"Infect. Agent Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e037505","DOI":"10.1136\/bmjopen-2020-037505","article-title":"Global and regional incidence, mortality and disability-adjusted life-years for Epstein-Barr virus-attributable malignancies, 1990\u20132017","volume":"10","author":"Khan","year":"2020","journal-title":"BMJ Open"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/s41579-019-0249-7","article-title":"Latency and lytic replication in Epstein-Barr virus-associated oncogenesis","volume":"17","author":"Munz","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"P1.293","DOI":"10.1212\/WNL.86.16_supplement.P1.293","article-title":"Epstein Barr Virus Encephalitis in Adults: A Case Series (P1.293)","volume":"86","author":"Khanal","year":"2016","journal-title":"Neurology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.oooo.2021.03.015","article-title":"Oral hairy leukoplakia: A series of 45 cases in immunocompetent patients","volume":"132","author":"Almazyad","year":"2021","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11899-013-0162-5","article-title":"Post-transplant lymphoproliferative disease (PTLD): Risk factors, diagnosis, and current treatment strategies","volume":"8","author":"Nelson","year":"2013","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s13195-021-00905-5","article-title":"Herpesvirus infections and Alzheimer\u2019s disease: A Mendelian randomization study","volume":"13","author":"Huang","year":"2021","journal-title":"Alzheimers Res. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Pyzik, A., Grywalska, E., Matyjaszek-Matuszek, B., Ludian, J., Kiszczak-Bochynska, E., Smolen, A., Rolinski, J., and Pyzik, D. (2019). Does the Epstein-Barr Virus Play a Role in the Pathogenesis of Graves\u2019 Disease?. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20133145"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"587380","DOI":"10.3389\/fimmu.2020.587380","article-title":"Epstein-Barr Virus and Systemic Autoimmune Diseases","volume":"11","author":"Houen","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1126\/science.abj8222","article-title":"Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis","volume":"375","author":"Bjornevik","year":"2022","journal-title":"Science"},{"key":"ref_27","unstructured":"Knipe, D.M., and Howley, P.M. (2013). Fields Virology, Lippincott Williams & Wilkins. [6th ed.]."},{"key":"ref_28","unstructured":"Knipe, D.M., and Howley, P.M. (2013). Field\u2019s Virology, Lippincott Williams & Wilkins. [6th ed.]."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.2217\/fvl.15.80","article-title":"EBV glycoproteins: Where are we now?","volume":"10","year":"2015","journal-title":"Future Virol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41579-020-00448-w","article-title":"The structural basis of herpesvirus entry","volume":"19","author":"Connolly","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"11162","DOI":"10.1128\/JVI.74.23.11162-11172.2000","article-title":"Epstein-Barr virus that lacks glycoprotein gN is impaired in assembly and infection","volume":"74","author":"Lake","year":"2000","journal-title":"J. Virol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Gram, A.M., Oosenbrug, T., Lindenbergh, M.F., Bull, C., Comvalius, A., Dickson, K.J., Wiegant, J., Vrolijk, H., Lebbink, R.J., and Wolterbeek, R. (2016). The Epstein-Barr Virus Glycoprotein gp150 Forms an Immune-Evasive Glycan Shield at the Surface of Infected Cells. PLoS Pathog., 12.","DOI":"10.1371\/journal.ppat.1005550"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Bu, G.L., Xie, C., Kang, Y.F., Zeng, M.S., and Sun, C. (2022). How EBV Infects: The Tropism and Underlying Molecular Mechanism for Viral Infection. Viruses, 14.","DOI":"10.3390\/v14112372"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Murata, T., Sugimoto, A., Inagaki, T., Yanagi, Y., Watanabe, T., Sato, Y., and Kimura, H. (2021). Molecular Basis of Epstein-Barr Virus Latency Establishment and Lytic Reactivation. Viruses, 13.","DOI":"10.3390\/v13122344"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/rmv.1786","article-title":"Modes of infection and oncogenesis by the Epstein-Barr virus","volume":"24","author":"Murata","year":"2014","journal-title":"Rev. Med. Virol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Sausen, D.G., Bhutta, M.S., Gallo, E.S., Dahari, H., and Borenstein, R. (2021). Stress-Induced Epstein-Barr Virus Reactivation. Biomolecules, 11.","DOI":"10.3390\/biom11091380"},{"key":"ref_37","first-page":"40","article-title":"Epstein-Barr virus-associated B-cell lymphoproliferative disorders and lymphomas: A review","volume":"52","author":"Salas","year":"2020","journal-title":"Pathology"},{"key":"ref_38","first-page":"e2009013","article-title":"EBV in Hodgkin Lymphoma","volume":"1","author":"Massini","year":"2009","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/978-981-10-7230-7_17","article-title":"EBV-Encoded Latent Genes","volume":"1045","author":"Kanda","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_40","first-page":"3","article-title":"Ebna1","volume":"391","author":"Frappier","year":"2015","journal-title":"Curr. Top Microbiol. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cell.2020.12.022","article-title":"Cell-cycle-dependent EBNA1-DNA crosslinking promotes replication termination at oriP and viral episome maintenance","volume":"184","author":"Dheekollu","year":"2021","journal-title":"Cell"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Wang, Y., Du, S., Zhu, C., Wang, C., Yu, N., Lin, Z., Gan, J., Guo, Y., Huang, X., and He, Y. (2020). STUB1 is targeted by the SUMO-interacting motif of EBNA1 to maintain Epstein-Barr Virus latency. PLoS Pathog., 16.","DOI":"10.1371\/journal.ppat.1008447"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.3390\/v4091537","article-title":"Contributions of Epstein-Barr nuclear antigen 1 (EBNA1) to cell immortalization and survival","volume":"4","author":"Frappier","year":"2012","journal-title":"Viruses"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41388-019-1003-3","article-title":"The Epstein-Barr virus nuclear antigen-1 upregulates the cellular antioxidant defense to enable B-cell growth transformation and immortalization","volume":"39","author":"Wang","year":"2020","journal-title":"Oncogene"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/0042-6822(91)90893-G","article-title":"Early events in Epstein-Barr virus infection of human B lymphocytes","volume":"181","author":"Alfieri","year":"1991","journal-title":"Virology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e01723-19","DOI":"10.1128\/mBio.01723-19","article-title":"First Days in the Life of Naive Human B Lymphocytes Infected with Epstein-Barr Virus","volume":"10","author":"Pich","year":"2019","journal-title":"mBio"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"9558","DOI":"10.1073\/pnas.86.23.9558","article-title":"Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation","volume":"86","author":"Cohen","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000343753","article-title":"EBNA-2 -deleted Epstein-Barr virus from P3HR-1 can infect rabbits with lower efficiency than prototype Epstein-Barr virus from B95-8","volume":"56","author":"Sano","year":"2013","journal-title":"Intervirology"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Li, C., Romero-Masters, J.C., Huebner, S., Ohashi, M., Hayes, M., Bristol, J.A., Nelson, S.E., Eichelberg, M.R., Van Sciver, N., and Ranheim, E.A. (2020). EBNA2-deleted Epstein-Barr virus (EBV) isolate, P3HR1, causes Hodgkin-like lymphomas and diffuse large B cell lymphomas with type II and Wp-restricted latency types in humanized mice. PLoS Pathog., 16.","DOI":"10.1371\/journal.ppat.1008590"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1099\/vir.0.81153-0","article-title":"Epstein-Barr virus-induced B-cell transformation: Quantitating events from virus binding to cell outgrowth","volume":"86","author":"Baldwin","year":"2005","journal-title":"J. Gen. Virol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1128\/jvi.64.3.1002-1013.1990","article-title":"Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23","volume":"64","author":"Cordier","year":"1990","journal-title":"J. Virol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.virol.2021.02.004","article-title":"RNAseq analysis identifies involvement of EBNA2 in PD-L1 induction during Epstein-Barr virus infection of primary B cells","volume":"557","author":"Yanagi","year":"2021","journal-title":"Virology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41375-018-0178-x","article-title":"Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas","volume":"33","author":"Anastasiadou","year":"2019","journal-title":"Leukemia"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Su, C., Lu, F., Soldan, S.S., Lamontagne, R.J., Tang, H.Y., Napoletani, G., Farrell, P.J., Tempera, I., Kossenkov, A.V., and Lieberman, P.M. (2021). EBNA2 driven enhancer switching at the CIITA-DEXI locus suppresses HLA class II gene expression during EBV infection of B-lymphocytes. PLoS Pathog., 17.","DOI":"10.1371\/journal.ppat.1009834"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"M\u00fcnz, C. (2015). Epstein Barr Virus Volume 2: One Herpes Virus: Many Diseases, Springer International Publishing.","DOI":"10.1007\/978-3-319-22834-1"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1038\/emm.2014.84","article-title":"Epstein-Barr virus latent genes","volume":"47","author":"Kang","year":"2015","journal-title":"Exp. Mol. Med."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Lu, F., Chen, H.S., Kossenkov, A.V., DeWispeleare, K., Won, K.J., and Lieberman, P.M. (2016). EBNA2 Drives Formation of New Chromosome Binding Sites and Target Genes for B-Cell Master Regulatory Transcription Factors RBP-jkappa and EBF1. PLoS Pathog., 12.","DOI":"10.1371\/journal.ppat.1005339"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"10657","DOI":"10.1093\/nar\/gkab787","article-title":"Modulation of alternative splicing during early infection of human primary B lymphocytes with Epstein-Barr virus (EBV): A novel function for the viral EBNA-LP protein","volume":"49","author":"Manet","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Szymula, A., Palermo, R.D., Bayoumy, A., Groves, I.J., Ba Abdullah, M., Holder, B., and White, R.E. (2018). Epstein-Barr virus nuclear antigen EBNA-LP is essential for transforming naive B cells, and facilitates recruitment of transcription factors to the viral genome. PLoS Pathog., 14.","DOI":"10.1371\/journal.ppat.1006890"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3389\/fmicb.2016.00457","article-title":"Role of EBNA-3 Family Proteins in EBV Associated B-cell Lymphomagenesis","volume":"7","author":"Bhattacharjee","year":"2016","journal-title":"Front. Microbiol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1128\/jvi.67.4.2014-2025.1993","article-title":"Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation","volume":"67","author":"Tomkinson","year":"1993","journal-title":"J. Virol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4506","DOI":"10.1128\/JVI.79.7.4506-4509.2005","article-title":"Epstein-Barr virus with the latent infection nuclear antigen 3B completely deleted is still competent for B-cell growth transformation in vitro","volume":"79","author":"Chen","year":"2005","journal-title":"J. Virol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e00238-19","DOI":"10.1128\/JVI.00238-19","article-title":"Mechanisms of B-Cell Oncogenesis Induced by Epstein-Barr Virus","volume":"93","author":"Saha","year":"2019","journal-title":"J. Virol."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Tursiella, M.L., Bowman, E.R., Wanzeck, K.C., Throm, R.E., Liao, J., Zhu, J., and Sample, C.E. (2014). Epstein-Barr virus nuclear antigen 3A promotes cellular proliferation by repression of the cyclin-dependent kinase inhibitor p21WAF1\/CIP1. PLoS Pathog., 10.","DOI":"10.1371\/journal.ppat.1004415"},{"key":"ref_65","first-page":"61","article-title":"The EBNA3 Family: Two Oncoproteins and a Tumour Suppressor that Are Central to the Biology of EBV in B Cells","volume":"391","author":"Allday","year":"2015","journal-title":"Curr. Top Microbiol. Immunol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1128\/JVI.00663-18","article-title":"Epstein-Barr Virus Nuclear Antigen 3C Facilitates Cell Proliferation by Regulating Cyclin D2","volume":"92","author":"Pei","year":"2018","journal-title":"J. Virol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1172\/JCI58092","article-title":"EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors","volume":"122","author":"White","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/0092-8674(85)90256-9","article-title":"An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells","volume":"43","author":"Wang","year":"1985","journal-title":"Cell"},{"key":"ref_69","first-page":"119","article-title":"The Latent Membrane Protein 1 (LMP1)","volume":"391","author":"Kieser","year":"2015","journal-title":"Curr. Top Microbiol. Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1038\/onc.2015.450","article-title":"Oxidative stress enables Epstein-Barr virus-induced B-cell transformation by posttranscriptional regulation of viral and cellular growth-promoting factors","volume":"35","author":"Chen","year":"2016","journal-title":"Oncogene"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1097\/PAS.0000000000001919","article-title":"Enhanced PD-L1 Expression in LMP1-positive Cells of Epstein-Barr Virus-associated Malignant Lymphomas and Lymphoproliferative Disorders: A Single-cell Resolution Analysis With Multiplex Fluorescence Immunohistochemistry and In Situ Hybridization","volume":"46","author":"Kume","year":"2022","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1182\/blood-2017-07-740993","article-title":"PD-1 expression and clinical PD-1 blockade in B-cell lymphomas","volume":"131","author":"Zhou","year":"2018","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s11899-020-00589-y","article-title":"PD-1\/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas","volume":"15","author":"Xie","year":"2020","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/978-0-387-70630-6_14","article-title":"LMP1 TRAFficking activates growth and survival pathways","volume":"597","author":"Soni","year":"2007","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1111\/j.1600-6143.2009.02781.x","article-title":"Activation of the JAK\/STAT pathway in Epstein Barr virus+-associated posttransplant lymphoproliferative disease: Role of interferon-gamma","volume":"9","author":"Vaysberg","year":"2009","journal-title":"Am. J. Transplant."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.1128\/JVI.01703-10","article-title":"Epstein-Barr virus LMP1 activates EGFR, STAT3, and ERK through effects on PKCdelta","volume":"85","author":"Kung","year":"2011","journal-title":"J. Virol."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Vrzalikova, K., Ibrahim, M., Nagy, E., Vockerodt, M., Perry, T., Wei, W., Woodman, C., and Murray, P. (2018). Co-Expression of the Epstein-Barr Virus-Encoded Latent Membrane Proteins and the Pathogenesis of Classic Hodgkin Lymphoma. Cancers, 10.","DOI":"10.3390\/cancers10090285"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1006\/viro.1997.8690","article-title":"The immunoreceptor tyrosine-based activation motif of Epstein-Barr virus LMP2A is essential for blocking BCR-mediated signal transduction","volume":"235","author":"Fruehling","year":"1997","journal-title":"Virology"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"26318","DOI":"10.1073\/pnas.2007946117","article-title":"Rewiring of B cell receptor signaling by Epstein-Barr virus LMP2A","volume":"117","author":"Fish","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1128\/JVI.01723-07","article-title":"Latent membrane protein 2B regulates susceptibility to induction of lytic Epstein-Barr virus infection","volume":"82","author":"Rechsteiner","year":"2008","journal-title":"J. Virol."},{"key":"ref_81","first-page":"151","article-title":"Latent Membrane Protein 2 (LMP2)","volume":"391","author":"Cen","year":"2015","journal-title":"Curr. Top Microbiol. Immunol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"20160271","DOI":"10.1098\/rstb.2016.0271","article-title":"Epstein-Barr virus-associated lymphomas","volume":"372","author":"Rickinson","year":"2017","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/path.4459","article-title":"The Epstein-Barr virus and the pathogenesis of lymphoma","volume":"235","author":"Vockerodt","year":"2015","journal-title":"J. Pathol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/ajh.25760","article-title":"EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Beltran","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/00000478-200301000-00003","article-title":"Senile EBV+ B-cell lymphoproliferative disorders: A clinicopathologic study of 22 patients","volume":"27","author":"Oyama","year":"2003","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/pin.12946","article-title":"Age-related EBV-associated B-cell lymphoproliferative disorders and other EBV+ lymphoproliferative diseases: New insights into immune escape and immunodeficiency through staining with anti-PD-L1 antibody clone SP142","volume":"70","author":"Sakakibara","year":"2020","journal-title":"Pathol. Int."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jim.2018.08.005","article-title":"Aging and the immune system: An overview","volume":"463","year":"2018","journal-title":"J. Immunol. Methods"},{"key":"ref_88","first-page":"8947","article-title":"Clinical features and survival impact of EBV-positive diffuse large B-Cell lymphoma with different age cutoffs","volume":"24","author":"Nan","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.7314\/APJCP.2016.17.4.2285","article-title":"Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma: Is It Different between Over and Under 50 Years of Age?","volume":"17","author":"Monabati","year":"2016","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.cellsig.2014.12.003","article-title":"Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia","volume":"27","author":"Wang","year":"2015","journal-title":"Cell Signal."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1600-065X.2012.01114.x","article-title":"S1PR2 links germinal center confinement and growth regulation","volume":"247","author":"Green","year":"2012","journal-title":"Immunol. Rev."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1182\/blood-2017-10-810630","article-title":"The tumor suppressive TGF-beta\/SMAD1\/S1PR2 signaling axis is recurrently inactivated in diffuse large B-cell lymphoma","volume":"131","author":"Stelling","year":"2018","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/path.5237","article-title":"Regulation of S1PR2 by the EBV oncogene LMP1 in aggressive ABC-subtype diffuse large B-cell lymphoma","volume":"248","author":"Vockerodt","year":"2019","journal-title":"J. Pathol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"14421","DOI":"10.1073\/pnas.1921139117","article-title":"Functional interplay of Epstein-Barr virus oncoproteins in a mouse model of B cell lymphomagenesis","volume":"117","author":"Sommermann","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"5907","DOI":"10.1182\/blood-2010-09-307710","article-title":"Down-regulation of BLIMP1alpha by the EBV oncogene, LMP-1, disrupts the plasma cell differentiation program and prevents viral replication in B cells: Implications for the pathogenesis of EBV-associated B-cell lymphomas","volume":"117","author":"Vrzalikova","year":"2011","journal-title":"Blood"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1128\/JVI.01928-16","article-title":"Latent Membrane Protein 1 (LMP1) and LMP2A Collaborate To Promote Epstein-Barr Virus-Induced B Cell Lymphomas in a Cord Blood-Humanized Mouse Model but Are Not Essential","volume":"91","author":"Ma","year":"2017","journal-title":"J. Virol."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Nagel, S., MacLeod, R.A.F., Meyer, C., Kaufmann, M., and Drexler, H.G. (2018). NKL homeobox gene activities in B-cell development and lymphomas. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0205537"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Nagel, S., Uphoff, C.C., Dirks, W.G., Pommerenke, C., Meyer, C., and Drexler, H.G. (2019). Epstein-Barr virus (EBV) activates NKL homeobox gene HLX in DLBCL. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0216898"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/modpathol.2012.52","article-title":"EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation","volume":"25","author":"Odqvist","year":"2012","journal-title":"Mod. Pathol."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Chabay, P. (2021). Advances in the Pathogenesis of EBV-Associated Diffuse Large B Cell Lymphoma. Cancers, 13.","DOI":"10.3390\/cancers13112717"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1080\/08998280.2017.11930222","article-title":"Epstein-Barr virus-positive diffuse large B-cell lymphoma","volume":"30","author":"Murthy","year":"2017","journal-title":"Bayl. Univ. Med. Cent. Proc."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Pei, Y., Wong, J.H.Y., and Robertson, E.S. (2020). Targeted Therapies for Epstein-Barr Virus-Associated Lymphomas. Cancers, 12.","DOI":"10.3390\/cancers12092565"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1007\/s00277-020-04005-6","article-title":"A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): Results of the final analysis","volume":"99","author":"Yoon","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"10029","DOI":"10.1128\/JVI.02241-06","article-title":"Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells","volume":"81","author":"Zou","year":"2007","journal-title":"J. Virol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/bjh.12172","article-title":"Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression","volume":"160","author":"Zhang","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1182\/blood-2021-151824","article-title":"Phase 2 Study of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin Lymphomas","volume":"138","author":"Yilmaz","year":"2021","journal-title":"Blood"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1146\/annurev.immunol.25.022106.141527","article-title":"Improving T cell therapy for cancer","volume":"25","author":"Leen","year":"2007","journal-title":"Annu. Rev. Immunol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"LBA-6","DOI":"10.1182\/blood.V128.22.LBA-6.LBA-6","article-title":"Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1","volume":"128","author":"Sattva","year":"2016","journal-title":"Blood"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Wudhikarn, K., Alarcon Tomas, A., Flynn, J.R., Devlin, S.M., Brower, J., Bachanova, V., Nastoupil, L.J., McGuirk, J.P., Maziarz, R.T., and Oluwole, O.O. (2022). Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy. Blood Adv.","DOI":"10.1182\/bloodadvances.2022008294"},{"key":"ref_111","unstructured":"Viracta Therapeutics, Inc. (2023, February 08). An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed\/Refractory Lymphomas, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05011058."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1182\/blood-2021-152603","article-title":"Nanatinostat (Nstat) and Valganciclovir (VGCV) in Relapsed\/Refractory (R\/R) Epstein-Barr Virus-Positive (EBV+) Lymphomas: Final Results from the Phase 1b\/2 VT3996-201 Study","volume":"138","author":"Haverkos","year":"2021","journal-title":"Blood"},{"key":"ref_113","unstructured":"The First Affiliated Hospital with Nanjing Medical University (2023, February 09). Sintilimab in Combination With R-CHOP in Patients With Treatment-Naive EBV-Positive DLBCL, NOS, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04181489."},{"key":"ref_114","unstructured":"Aggarwal, P., and Limaiem, F. (2022). StatPearls, StatPearls Publishing."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood.2019000568","article-title":"An etiological role for the Epstein-Barr virus in the pathogenesis of classical Hodgkin lymphoma","volume":"134","author":"Murray","year":"2019","journal-title":"Blood"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/annonc\/2.suppl_2.33","article-title":"The nature of Hodgkin and Reed-Sternberg cells, their association with EBV, and their relationship to anaplastic large-cell lymphoma","volume":"2","author":"Stein","year":"1991","journal-title":"Ann. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/s41375-021-01204-6","article-title":"Molecular biology of Hodgkin lymphoma","volume":"35","author":"Weniger","year":"2021","journal-title":"Leukemia"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1038\/s41379-020-0608-y","article-title":"Correction: Frequent traces of EBV infection in Hodgkin and non-Hodgkin lymphomas classified as EBV-negative by routine methods: Expanding the landscape of EBV-related lymphomas","volume":"33","author":"Mundo","year":"2020","journal-title":"Mod. Pathol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/PAS.0000000000000107","article-title":"EBV may be expressed in the LP cells of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) in both children and adults","volume":"38","author":"Huppmann","year":"2014","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/path.2384","article-title":"The Epstein-Barr virus oncoprotein, latent membrane protein-1, reprograms germinal centre B cells towards a Hodgkin\u2019s Reed-Sternberg-like phenotype","volume":"216","author":"Vockerodt","year":"2008","journal-title":"J. Pathol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"4908","DOI":"10.1038\/sj.onc.1205629","article-title":"Loss of B cell identity correlates with loss of B cell-specific transcription factors in Hodgkin\/Reed-Sternberg cells of classical Hodgkin lymphoma","volume":"21","author":"Hertel","year":"2002","journal-title":"Oncogene"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1080\/10428194.2019.1607330","article-title":"Epstein-Barr virus-encoded LMP1 induces ectopic CD137 expression on Hodgkin and Reed-Sternberg cells via the PI3K-AKT-mTOR pathway","volume":"60","author":"Aravinth","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1158\/0008-5472.CAN-12-3849","article-title":"Expression of CD137 on Hodgkin and Reed-Sternberg cells inhibits T-cell activation by eliminating CD137 ligand expression","volume":"73","author":"Ho","year":"2013","journal-title":"Cancer Res."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Jorapur, A., Marshall, L.A., Jacobson, S., Xu, M., Marubayashi, S., Zibinsky, M., Hu, D.X., Robles, O., Jackson, J.J., and Baloche, V. (2022). EBV+ tumors exploit tumor cell-intrinsic and -extrinsic mechanisms to produce regulatory T cell-recruiting chemokines CCL17 and CCL22. PLoS Pathog., 18.","DOI":"10.1371\/journal.ppat.1010200"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1128\/JVI.78.4.1665-1674.2004","article-title":"Selective induction of Th2-attracting chemokines CCL17 and CCL22 in human B cells by latent membrane protein 1 of Epstein-Barr virus","volume":"78","author":"Nakayama","year":"2004","journal-title":"J. Virol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.canlet.2019.03.053","article-title":"Epstein-Barr virus-positive pyothorax-associated lymphoma expresses CCL17 and CCL22 chemokines that attract CCR4-expressing regulatory T cells","volume":"453","author":"Higuchi","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/cas.14833","article-title":"Epstein-Barr virus latent membrane protein-1 upregulates autophagy and promotes viability in Hodgkin lymphoma: Implications for targeted therapy","volume":"112","author":"Lin","year":"2021","journal-title":"Cancer Sci."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s41065-022-00230-3","article-title":"Gene expression trend changes in breast cancer populations over two decades: Insights from The Cancer Genome Atlas database","volume":"159","author":"Wu","year":"2022","journal-title":"Hereditas"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Nagai, L.A.E., Park, S.J., and Nakai, K. (2019). Analyzing the 3D chromatin organization coordinating with gene expression regulation in B-cell lymphoma. BMC Med. Genom., 11.","DOI":"10.1186\/s12920-018-0437-8"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","article-title":"Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma","volume":"131","author":"Spina","year":"2018","journal-title":"Blood"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.1182\/blood-2003-04-1018","article-title":"Epstein-Barr Virus (EBV) LMP2A induces alterations in gene transcription similar to those observed in Reed-Sternberg cells of Hodgkin lymphoma","volume":"102","author":"Portis","year":"2003","journal-title":"Blood"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1182\/blood-2008-06-160937","article-title":"Epstein-Barr virus latent membrane protein 2A exploits Notch1 to alter B-cell identity in vivo","volume":"113","author":"Anderson","year":"2009","journal-title":"Blood"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/jmv.25381","article-title":"Epstein-Barr virus LMP2A utilizes Syk and PI3K to activate NF-kappaB in B-cell lymphomas to increase MIP-1alpha production","volume":"91","author":"Incrocci","year":"2019","journal-title":"J. Med. Virol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"30","DOI":"10.21037\/aol-21-8","article-title":"The contributions of ebv to the pathogenesis of classical hodgkin lymphoma","volume":"5","author":"Vrzalikova","year":"2021","journal-title":"Ann. Lymphoma"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1182\/blood-2006-11-059881","article-title":"Down-regulation of the TGF-beta target gene, PTPRK, by the Epstein-Barr virus encoded EBNA1 contributes to the growth and survival of Hodgkin lymphoma cells","volume":"111","author":"Flavell","year":"2008","journal-title":"Blood"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2353\/ajpath.2008.070845","article-title":"Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin\u2019s lymphoma cells mediates Up-regulation of CCL20 and the migration of regulatory T cells","volume":"173","author":"Baumforth","year":"2008","journal-title":"Am. J. Pathol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.mayocp.2015.07.005","article-title":"Hodgkin Lymphoma: Diagnosis and Treatment","volume":"90","author":"Ansell","year":"2015","journal-title":"Mayo Clin. Proc."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/hon.2590","article-title":"Treatment of elderly Hodgkin lymphoma patients","volume":"37","author":"Engert","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1182\/blood-2004-09-3759","article-title":"Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: A population-based study","volume":"106","author":"Jarrett","year":"2005","journal-title":"Blood"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: Implications for targeted therapy","volume":"18","author":"Green","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00277-022-05054-9","article-title":"Anti-CD30 antibody-drug conjugate therapy in lymphoma: Current knowledge, remaining controversies, and future perspectives","volume":"102","author":"Prince","year":"2023","journal-title":"Ann. Hematol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1182\/blood.2020009178","article-title":"Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results","volume":"138","author":"Advani","year":"2021","journal-title":"Blood"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.3324\/haematol.2019.243238","article-title":"Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: The phase II HOVON\/LLPC Transplant BRaVE study","volume":"106","author":"Kersten","year":"2021","journal-title":"Haematologica"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood.2019003127","article-title":"Brentuximab vedotin with chemotherapy for stage III\/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study","volume":"135","author":"Straus","year":"2020","journal-title":"Blood"},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Meier, J.A., Savoldo, B., and Grover, N.S. (2022). The Emerging Role of CAR T Cell Therapy in Relapsed\/Refractory Hodgkin Lymphoma. J. Pers. Med., 12.","DOI":"10.3390\/jpm12020197"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s40164-022-00323-9","article-title":"Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed\/refractory CD30(+) lymphoma","volume":"11","author":"Zhang","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1146\/annurev-immunol-032414-112326","article-title":"The immunology of Epstein-Barr virus-induced disease","volume":"33","author":"Taylor","year":"2015","journal-title":"Annu. Rev. Immunol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"734471","DOI":"10.3389\/fimmu.2021.734471","article-title":"Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases","volume":"12","author":"Cui","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.7150\/thno.26823","article-title":"EBNA1-targeted inhibitors: Novel approaches for the treatment of Epstein-Barr virus-associated cancers","volume":"8","author":"Jiang","year":"2018","journal-title":"Theranostics"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1056\/NEJMra2025746","article-title":"Burkitt\u2019s Lymphoma","volume":"387","author":"Roschewski","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S0140-6736(64)91524-7","article-title":"Virus Particles in Cultured Lymphoblasts from Burkitt\u2019s Lymphoma","volume":"1","author":"Epstein","year":"1964","journal-title":"Lancet"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3389\/fonc.2019.00713","article-title":"The Global Landscape of EBV-Associated Tumors","volume":"9","author":"Rickinson","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/eji.202249820","article-title":"Epstein-Barr virus and malaria upregulate AID and APOBEC3 enzymes, but only AID seems to play a major mutagenic role in Burkitt lymphoma","volume":"52","author":"Summerauer","year":"2022","journal-title":"Eur. J. Immunol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"22","DOI":"10.21037\/aol-21-18","article-title":"Reframing Burkitt lymphoma: Virology not epidemiology defines clinical variants","volume":"5","author":"Rochford","year":"2021","journal-title":"Ann. Lymphoma"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"226","DOI":"10.5483\/BMBRep.2016.49.4.260","article-title":"Targeted disruption of EBNA1 in EBV-infected cells attenuated cell growth","volume":"49","author":"Noh","year":"2016","journal-title":"BMB Rep."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.bbrc.2019.02.108","article-title":"The interaction between Vav1 and EBNA1 promotes survival of Burkitt\u2019s lymphoma cells by down-regulating the expression of Bim","volume":"511","author":"Wang","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/j.1365-2141.2006.06094.x","article-title":"Overexpression of the VAV proto-oncogene product is associated with B-cell chronic lymphocytic leukaemia displaying loss on 13q","volume":"133","author":"Hernandez","year":"2006","journal-title":"Br. J. Haematol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/sj.onc.1210668","article-title":"Two Epstein-Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim: Clues to the pathogenesis of Burkitt\u2019s lymphoma","volume":"27","author":"Anderton","year":"2008","journal-title":"Oncogene"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"224","DOI":"10.18632\/oncotarget.4399","article-title":"Virus-encoded microRNA contributes to the molecular profile of EBV-positive Burkitt lymphomas","volume":"7","author":"Piccaluga","year":"2016","journal-title":"Oncotarget"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/onc.2013.71","article-title":"Epstein-Barr virus maintains lymphomas via its miRNAs","volume":"33","author":"Vereide","year":"2014","journal-title":"Oncogene"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1002\/bab.2233","article-title":"Caspase-3: Structure, function, and biotechnological aspects","volume":"69","author":"Asadi","year":"2022","journal-title":"Biotechnol. Appl. Biochem."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12985-016-0602-7","article-title":"Epstein-Barr viral microRNAs target caspase 3","volume":"13","author":"Harold","year":"2016","journal-title":"Virol. J."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.3892\/mmr.2017.6173","article-title":"EBV-BART-6-3p and cellular microRNA-197 compromise the immune defense of host cells in EBV-positive Burkitt lymphoma","volume":"15","author":"Zhang","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"4114","DOI":"10.12659\/MSM.897306","article-title":"Epstein-Barr Virus (EBV)-BamHI-A Rightward Transcript (BART)-6 and Cellular MicroRNA-142 Synergistically Compromise Immune Defense of Host Cells in EBV-Positive Burkitt Lymphoma","volume":"22","author":"Zhou","year":"2016","journal-title":"Med. Sci. Monit."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1146\/annurev-med-052218-125823","article-title":"The Clinical Spectrum of PTEN Mutations","volume":"71","author":"Yehia","year":"2020","journal-title":"Annu. Rev. Med."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1182\/blood.2019004099","article-title":"The treatment of Burkitt lymphoma in adults","volume":"137","author":"Crombie","year":"2021","journal-title":"Blood"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1182\/blood.2020006926","article-title":"Burkitt lymphoma in the modern era: Real-world outcomes and prognostication across 30 US cancer centers","volume":"137","author":"Evens","year":"2021","journal-title":"Blood"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"838817","DOI":"10.3389\/fonc.2022.838817","article-title":"Treatment Advances in EBV Related Lymphoproliferative Diseases","volume":"12","author":"Lv","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bbmt.2012.11.016","article-title":"Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: A report from the center for international blood and marrow transplant research","volume":"19","author":"Maramattom","year":"2013","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"E114","DOI":"10.1002\/ajh.24720","article-title":"Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia\/lymphoma","volume":"92","author":"Short","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/s41409-018-0235-0","article-title":"CAR T cells induce a complete response in refractory Burkitt Lymphoma","volume":"53","author":"Avigdor","year":"2018","journal-title":"Bone Marrow Transpl."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood.2019004126","article-title":"Epigenetic reprogramming sensitizes immunologically silent EBV+ lymphomas to virus-directed immunotherapy","volume":"135","author":"Dalton","year":"2020","journal-title":"Blood"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1038\/s41375-021-01313-2","article-title":"NK-\/T-cell lymphomas","volume":"35","author":"Wang","year":"2021","journal-title":"Leukemia"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref_176","doi-asserted-by":"crossref","unstructured":"Montes-Mojarro, I.A., Fend, F., and Quintanilla-Martinez, L. (2021). EBV and the Pathogenesis of NK\/T Cell Lymphoma. Cancers, 13.","DOI":"10.3390\/cancers13061414"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1007\/s12015-020-10112-8","article-title":"Latent Membrane Protein 1 Promotes Tumorigenesis Through Upregulation of PGC1beta Signaling Pathway","volume":"17","author":"Feng","year":"2021","journal-title":"Stem Cell Rev. Rep."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1038\/onc.2012.529","article-title":"The PGC-1\/ERR signaling axis in cancer","volume":"32","author":"Deblois","year":"2013","journal-title":"Oncogene"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1002\/1878-0261.12363","article-title":"PGC1beta regulates multiple myeloma tumor growth through LDHA-mediated glycolytic metabolism","volume":"12","author":"Zhang","year":"2018","journal-title":"Mol. Oncol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1038\/s41375-020-0801-5","article-title":"HKDC1 C-terminal based peptides inhibit extranodal natural killer\/T-cell lymphoma by modulation of mitochondrial function and EBV suppression","volume":"34","author":"Chen","year":"2020","journal-title":"Leukemia"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.3892\/or.2015.4305","article-title":"LMP1 promotes nasal NK\/T-cell lymphoma cell function by eIF4E via NF-kappaB pathway","volume":"34","author":"Sun","year":"2015","journal-title":"Oncol. Rep."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"e923210","DOI":"10.12659\/MSM.923210","article-title":"Tumor-Derived Exosomal eIF4E as a Biomarker for Survival Prediction in Patients with Non-Small Cell Lung Cancer","volume":"26","author":"Dong","year":"2020","journal-title":"Med. Sci. Monit."},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Li, F., Sun, H., Li, Y., Bai, X., Dong, X., Zhao, N., Meng, J., Sun, B., and Zhang, D. (2021). High expression of eIF4E is associated with tumor macrophage infiltration and leads to poor prognosis in breast cancer. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-09010-0"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/ajh.23570","article-title":"Downregulation of miR-15a due to LMP1 promotes cell proliferation and predicts poor prognosis in nasal NK\/T-cell lymphoma","volume":"89","author":"Komabayashi","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/ijc.25969","article-title":"Monocytes enhance cell proliferation and LMP1 expression of nasal natural killer\/T-cell lymphoma cells by cell contact-dependent interaction through membrane-bound IL-15","volume":"130","author":"Ishii","year":"2012","journal-title":"Int. J. Cancer"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13045-022-01293-5","article-title":"How we treat NK\/T-cell lymphomas","volume":"15","author":"Tse","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/j.1365-2141.2005.05694.x","article-title":"Selective apoptosis of natural killer-cell tumours by l-asparaginase","volume":"130","author":"Ando","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_188","unstructured":"National Comprehensive Cancer Network (2023, February 25). T-Cell Lymphomas (Version 1.2023). Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/t-cell.pdf."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1007\/s00277-021-04558-0","article-title":"Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK\/T lymphoma: Results of a multicenter study","volume":"100","author":"Kim","year":"2021","journal-title":"Ann. Hematol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1182\/blood-2018-07-863654","article-title":"EBV\/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation","volume":"132","author":"McLaughlin","year":"2018","journal-title":"Blood"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/bjh.14879","article-title":"Allogeneic haematopoietic cell transplantation for extranodal natural killer\/T-cell lymphoma, nasal type: A CIBMTR analysis","volume":"182","author":"Kanate","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/mt.2015.91","article-title":"Long-term Outcome of Extranodal NK\/T Cell Lymphoma Patients Treated With Postremission Therapy Using EBV LMP1 and LMP2a-specific CTLs","volume":"23","author":"Cho","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1200\/JCO.2017.72.7602","article-title":"Primary CNS Lymphoma","volume":"35","author":"Grommes","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00066-014-0670-9","article-title":"Primary EBV-positive Hodgkin\u2019s lymphoma of the CNS under azathioprine treatment: Case report and review of the literature","volume":"190","author":"Henkenberens","year":"2014","journal-title":"Strahlenther. Onkol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1038\/s41467-022-30050-y","article-title":"The genomic and transcriptional landscape of primary central nervous system lymphoma","volume":"13","author":"Radke","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"e13528","DOI":"10.1200\/JCO.2019.37.15_suppl.e13528","article-title":"The impact of Epstein-Barr virus status on primary CNS lymphoma survival","volume":"37","author":"Prado","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1182\/blood.2019000633","article-title":"R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-alpha in primary CNS lymphoma","volume":"134","author":"Ferreri","year":"2019","journal-title":"Blood"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1158\/2159-8290.CD-17-0613","article-title":"Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma","volume":"7","author":"Grommes","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3109\/10428194.2012.698736","article-title":"Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma","volume":"54","author":"Nayak","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1002\/cncr.26709","article-title":"Pemetrexed in the treatment of relapsed\/refractory primary central nervous system lymphoma","volume":"118","author":"Raizer","year":"2012","journal-title":"Cancer"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1093\/annonc\/mdl070","article-title":"Prospective trial on topotecan salvage therapy in primary CNS lymphoma","volume":"17","author":"Fischer","year":"2006","journal-title":"Ann. Oncol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/sj.bjc.6603660","article-title":"Temozolomide as salvage treatment in primary brain lymphomas","volume":"96","author":"Reni","year":"2007","journal-title":"Br. J. Cancer"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1212\/WNL.0b013e31820f2d94","article-title":"Rituximab monotherapy for patients with recurrent primary CNS lymphoma","volume":"76","author":"Batchelor","year":"2011","journal-title":"Neurology"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2006-12-063008","article-title":"Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: Results of a phase 2 multicenter clinical trial","volume":"110","author":"Haque","year":"2007","journal-title":"Blood"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.0001-2815.2004.00227.x","article-title":"Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies","volume":"63","author":"Davis","year":"2004","journal-title":"Tissue Antigens"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S0140-6736(00)02879-8","article-title":"Epstein-Barr virus-targeted therapy for AIDS-related primary lymphoma of the central nervous system","volume":"356","author":"Slobod","year":"2000","journal-title":"Lancet"},{"key":"ref_207","doi-asserted-by":"crossref","unstructured":"Rozman, M., Korac, P., Jambrosic, K., and Zidovec Lepej, S. (2022). Progress in Prophylactic and Therapeutic EBV Vaccine Development Based on Molecular Characteristics of EBV Target Antigens. Pathogens, 11.","DOI":"10.3390\/pathogens11080864"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1136\/jclinpath-2019-205822","article-title":"Epstein-Barr virus (EBV) reactivation and therapeutic inhibitors","volume":"72","author":"Kerr","year":"2019","journal-title":"J. Clin. Pathol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/7\/2133\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:09:31Z","timestamp":1760123371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/7\/2133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,4]]},"references-count":208,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["cancers15072133"],"URL":"https:\/\/doi.org\/10.3390\/cancers15072133","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,4]]}}}